BoostME
Earlier prime-BOOST schedule to improve MEasles protection in high burden settings
Funder
Bill and Melinda Gates Foundation
Type of Study
Phase IIb, Randomised controlled trial, open label
Sponsor
University of Oxford
Country
Uganda
Chief Investigator
Prof Merryn Voysey (Co-chief Investigator: Prof Kirsty Le Doare)
Participants
Infants aged 6 months (23-28 weeks) at screening visit who have not received prior vaccination against measles
Summary
Primary Objectives:
- To compare protective measles antibody concentrations at 2.5 years of age in infants receiving an early (6 months) compared to standard (9 month) dose of MCV, and a booster dose at 18 months of age (Primary comparison 1)
- To compare protective measles antibody concentrations one month after a second dose of MCV given at 12 months (early) compared to standard (18 months), in those who received an early (6 months) first dose (Primary comparison 2)
Secondary Objectives:
- To describe the measles antibody concentrations one month after first dose in infants receiving an early (6 months) compared to standard (9 month) dose of MCV
- To describe the effect of maternal antibodies on infant humoral and cellular immune response to first and second doses in children vaccinated under different schedules
- To describe the effect of maternal HIV infection on infant antibody responses post MCV1 and MCV2 given at different schedules
- To describe the impact of different vaccination schedules on responses to the rubella component of the vaccine
Duration
October 2022 – October 2025
Collaborators
